LCTX Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own LCTX shares is 143, representing 50.56% of the company's common stock.

UBS GROUP AG, in the last quarter, reduced its stake in LCTX by -3.08% restricting it's holding to 140.07 thousand shares of worth nearly $207.31K. JANE STREET GROUP, LLC also lessened -36.1% of the LCTX shares from its portfolio, reducing its holding to 104.8 thousand shares of worth $155.10K. BARCLAYS PLC also shunned LCTX shares holding by -48.76% last quarter which brought its holding to 93.93 thousand shares worth $139.00K.

As per its latest 13F filing, SUSQUEHANNA INTERNATIONAL GROUP, LLP increased its stake in LCTX by 100% in the last quarter. The institutional holder raised its holding to 35.31 thousand shares having worth more than $52.25K. CITIGROUP INC also added 8.48% more shares of LCTX to its portfolio, raising its holding to 25.85 thousand shares of worth $38.26K. VICTORY CAPITAL MANAGEMENT INC also increased its LCTX shares holding by 5% which brought its holding to 24.67 thousand shares worth $36.51K.

The insider with the most stakes in LCTX is BRADSHER NEAL C , at the company. Additionally, LCTX stock is highly held by BROADWOOD PARTNERS LP and BROADWOOD PARTNERS, L.P. among others.

Company executives, directors, and other insiders own 0.44% percent of Lineage Cell Therapeutics, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which LCTX insiders have sold stock, totaling 0 shares. Insiders that have sold shares include HOGGE GARY S., RUSSELL ANGUS C., and ANDREWS DEBORAH J.

There have been 6 transaction(s) during the past 6-months in which Lineage Cell Therapeutics, Inc. insiders have bought stock, totalling 120500 shares

Around 8.45M Lineage Cell Therapeutics, Inc. shares are held by insiders, which represents about 0.44% of LCTX stock.

LCTX , BRADSHER NEAL C holds the largest portfolio of the company's shares. LCTX shares owned by BRADSHER total nearly 34.27 million.

SUSQUEHANNA INTERNATIONAL GROUP, LLP is the largest institutional owner in LCTX which holds 35.31 thousand shares worth $52.25K or 0.02% of the total LCTX shares outstanding followed by RATHBONES GROUP PLC with ownership of 35 thousand shares representing 0.02% of the LCTX ownership. TRUST CO OF TOLEDO NA /OH/ is the third largest stakeholder with 33.8 thousand shares or 0.02% of the ownership worth more than $50.02K.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the LCTX is concerned, it is a stock which is optionable.

Number of LCTX shares short is 15.94M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 228.31M shares of LCTX are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, LCTX has 146.34M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for LCTX is 35.21.